LO FRANCIS sold $2.2M of ADPT

LO FRANCIS (Chief People Officer) sold 95,842 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $22.51 ($22.18–$22.59, $2.16M total) across 3 trades over 2026-07-01 to 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LO FRANCIS
Published Jul 6, 2026, 11:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The newest fact is the specific sale size, price range, and that it was executed under a pre-arranged Rule 10b5-1 plan; this typically reduces the informational content versus discretionary selling.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a durable repricing.

03

What to watch

The disclosure does not state tax, diversification, or liquidity needs; without those details, interpreting directionality for fundamentals is unreliable.

Relevance 5/10Novelty 5/10Timing: Filed 2026-07-06 after-hours; reflects sales executed 2026-07-01 to 2026-07-02.

Background

The article is an SEC Form 4 insider transaction for Adaptive Biotechnologies’ Chief People Officer, reported via SEC EDGAR.

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Adaptive Biotechnologies insider Lo Francis sold 95,842 shares in open-market trades at $22.18–$22.59 per share under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and it provides sale pricing/size without any accompanying operational or guidance change.

Market effects

Minimal—single-company insider sale under 10b5-1 does not signal sector-wide change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be read by some traders as a mild negative signal about near-term risk/reward.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider sale disclosure.

  • Lo Francis

    Chief People Officer who sold shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.